Entries by Maren Kühr

Biopharma partnership intensifying purification

DSP?Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides ­selected insights on Catalent’s findings from the collaboration.

Biopharma partnership – intensifying purification

DSP Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides ­selected insights on Catalent’s findings from the collaboration.

Biomanufacturing: Step up and speak up

In a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.

Abivax appoints new CMO

France-based Abivax SA announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as its new Chief Medical Officer. He will assume the new role in the beginning of March.

BioSenic strengthens scientific team with new CSO

Dr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic’s cell therapy and autoimmune disease platform pipeline and be responsible for R&D programmes.

Have biotech stocks bottomed out?

Biotechnology was dramatically rewarded in the financial markets through much of 2020 and the first half of 2021, widely credited for providing the COVID-19 vaccines. This followed four already exceptional years in the financial markets, with the Nasdaq Biotech Index (NBI) hitting its all-time high of 5449.32 on 30 August 2021.